Pulmonary Manifestations of Systemic Lupus Erythematosus Among Adults in Aseer Region, Saudi Arabia

被引:4
作者
Alhammadi, Nouf A. [1 ]
Alqahtani, Hanan Saeed [2 ]
Mahmood, Syed Esam [3 ]
Alshahrani, Abdulrahman Arif [4 ]
Alahmari, Abdullaziz Motlaq A. [4 ]
Alshahrani, Abdullah Rashid Safer [4 ]
Badawi, Abdullah Saeed A. [4 ]
Alqahtani, Ali Mohammed Ali [4 ]
Alsalem, Abdullah Thabet A. [4 ]
Alqahtani, Mohammed Saeed M. Alsultan [4 ]
Gazzan, Mohammed Ali [4 ]
机构
[1] King Khalid Univ, Coll Med, Dept Med, Abha, Saudi Arabia
[2] Aseer Cent Hosp, Dept Internal Med & Rheumatol, Abha, Saudi Arabia
[3] King Khalid Univ, Coll Med, Dept Family & Community Med, Abha 62529, Saudi Arabia
[4] King Khalid Univ, Coll Med, Abha, Saudi Arabia
来源
INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2024年 / 17卷
关键词
Systemic lupus erythematosus; pulmonary manifestation; Anti-dsDNA antibodies; ANA; DISEASE;
D O I
10.2147/IJGM.S449068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nearly half of the Systemic lupus erythematosus (SLE) patients develop lung involvement. The study assessed the extent of pulmonary involvement among SLE patients and to identify the associated factors in the population. Methodology: This retrospective cohort study was conducted at Aseer Hospital and Khamis Myshat Hospital in the Southern region of Saudi Arabia. The study spanned from January 1, 2016, to June 3, 2023. Patient inclusion criteria encompassed individuals who received a definitive diagnosis and classification as per American College of Rheumatology criteria, while patients under 18 years of age and those with mixed connective tissue diseases were exclude. Results: A total of 247 participants were included. 41.7% (n=103) aged 41 years and older, 95.1% (n = 235) were females. Around 10.10% had diabetes mellitus and 17.00% had hypertension and hypothyroidism. Lupus Nephritis was in 15.40%. Chest involvement was reported in 21.9%, in the form of pleuritis (6.10%), pleural effusion (4.00%), and lupus pneumonitis (4.00%), interstitial lung disease (4.00%), pulmonary embolism (3.60%) of individuals, and pulmonary hemorrhage (2.80%). The respiratory symptoms reported by SLE were; dyspnea, cough, and chest pain each having a prevalence of around 18.0%. Palpitations have a relatively high occurrence at 13.80%. Meanwhile, hemoptysis (blood coughing) has a lower prevalence of 1.20%, and fever is reported at 2.80%. Having chronic kidney disease and hypertension were significantly associated with having pulmonary involvement; (chi 2=3.308, p=0.027) and (chi 2=7.782, Fisher's p=0.002) respectively. The seropositivity for antiphospholipid Abs, anti-CCP, and antids-DNA were significantly associated with pulmonary involvement (chi 2=3.239, =p=0.049), (chi 2=4.621, Fisher's p=0.023), and (chi 2=8.248, p=0.010) respectively. Conclusion: The study found that 21.9% of SLE patients experience chest involvement, with varying degrees of pulmonary for Anti-dsDNA were found to be significant associations with lung involvement, contributing to our understanding of SLE.
引用
收藏
页码:1007 / 1015
页数:9
相关论文
共 20 条
[1]   Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage [J].
Aguilera-Pickens, Georgina ;
Abud-Mendoza, Carlos .
REUMATOLOGIA CLINICA, 2018, 14 (05) :294-300
[2]   Pulmonary manifestations in systemic lupus erythematosus: Association with disease activity [J].
Alamoudi, Omer S. B. ;
Attar, Suzan M. .
RESPIROLOGY, 2015, 20 (03) :474-480
[3]   Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus [J].
Amarnani, Raj ;
Yeoh, Su-Ann ;
Denneny, Emma K. ;
Wincup, Chris .
FRONTIERS IN MEDICINE, 2021, 7
[4]   Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus [J].
Bakshi, Jyoti ;
Segura, Beatriz Tejera ;
Wincup, Christopher ;
Rahman, Anisur .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2018, 55 (03) :352-367
[5]   Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII:: factors predictive of pulmonary damage [J].
Bertoli, A. M. ;
Vila, L. M. ;
Apte, M. ;
Fessler, B. J. ;
Bastian, H. M. ;
Reveille, J. D. ;
Alarcon, G. S. .
LUPUS, 2007, 16 (06) :410-417
[6]   The respiratory system in connective tissue disorders [J].
Crestani, B .
ALLERGY, 2005, 60 (06) :715-734
[7]   Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus [J].
Fidler, L. ;
Keen, K. J. ;
Touma, Z. ;
Mittoo, S. .
LUPUS, 2016, 25 (09) :1004-1011
[8]   Pulmonary Complications of Systemic Lupus Erythematosus [J].
Hannah, Jennifer R. ;
D'Cruz, David P. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 40 (02) :227-234
[9]  
HELLMANN DB, 1995, J RHEUMATOL, V22, P455
[10]   Pulmonary Manifestations of Systemic Lupus Erythematosus [J].
Kamen, Diane L. ;
Strange, Charlie .
CLINICS IN CHEST MEDICINE, 2010, 31 (03) :479-+